Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 15/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 4/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990281 | 1.00 | PIK3CG (0.48) | PIK3CGPIK3CAPIM1PIM2IGF1R | |
| SCHEMBL3367020 | 1.00 | PIK3CG (0.48) | PIK3CGPIK3CAPIM1PIM2IGF1R | |
| SCHEMBL3363435 | 0.92 | PIM1 (0.47) | PIK3CGPIK3CAPIM1PIM2IGF1R | |
| SCHEMBL12990160 | 0.92 | PIM1 (0.47) | PIK3CGPIK3CAPIM1PIM2IGF1R | |
| SCHEMBL3363428 | 0.92 | PIM1 (0.47) | PIK3CGPIK3CAPIM1PIM2IGF1R | |
| SCHEMBL12990442 | 0.84 | PIM2 (0.48) | PIM1PIM2CSNK2A2CSNK2A1 | |
| SCHEMBL3366653 | 0.81 | PIM2 (0.48) | PIM1PIM2CSNK2A2CSNK2A1 | |
| SCHEMBL3362857 | 0.80 | PIM2 (0.51) | PIM1PIM2CSNK2A2CSNK2A1 | |
| SCHEMBL3362852 | 0.80 | PIM2 (0.51) | PIM1PIM2CSNK2A2CSNK2A1 | |
| SCHEMBL704231 | 0.79 | PIM2 (0.74) | PIM1PIM2CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | PIK3CG 456/4885PIK3CA 496/4885PIM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.